A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/17 (2006.01) A61K 39/395 (2006.01) A61P 3/10 (2006.01) C07K 19/00 (2006.01)
Patent
CA 2567795
Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO: 2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.
Cette invention concerne des méthodes de traitement du diabète chez les mammifères, en particulier chez les êtres humains, faisant appel au blocage ou à l'inhibition de l'activité induite par le VEGF. Un inhibiteur préféré de l'activité induite par le VEGF est un antagoniste du VEGF tel que la protéine de fusion piège du VEGF de séquence SEQ ID NO:2 capable de se lier au VEGF et de bloquer le VEGF. La méthode de cette invention peut être combinée à d'autres thérapies, telles que l'insulinothérapie.
Hsin Chieh Lin
Jingtai Cao
Li-Hsien Wang
Sleeman Mark W.
Wiegand Stanley J.
Blake Cassels & Graydon Llp
Regeneron Pharmaceuticals Inc.
LandOfFree
Methods of treating type i diabetes by blocking... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating type i diabetes by blocking..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating type i diabetes by blocking... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1419140